Advanced Oncotherapy PLC Exercise of Warrants and Issue of Equity (7181L)

TIDMAVO

RNS Number : 7181L

Advanced Oncotherapy PLC

09 September 2019

9 September 2019

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Exercise of Warrants and Issue of Equity

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it today issued 2,400 new ordinary shares of 25 pence in the Company ("New Ordinary Shares") pursuant to the exercise of warrants at an exercise price of 150 pence per share. The New Ordinary Shares will rank pari passu in all respects with the existing Ordinary Shares of the Company. The consideration for the exercise of the warrants amounts to GBP3,600 which has been received by the Company.

Application has been made for the 2,400 New Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will occur on or about 13 September 2019.

Total voting rights

Following Admission, the Company's enlarged issued share capital will comprise 230,228,494 ordinary shares of 25 pence each, with one voting right per share ("Ordinary Shares"). The Company does not hold any ordinary shares in treasury and therefore the total number of Ordinary Shares with voting rights in the Company is 230,228,494.

The above figure of 230,228,494 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

 
  Advanced Oncotherapy Plc                                                    www.avoplc.com 
  Dr. Michael Sinclair, Executive                                   Tel: [phone] 
   Chairman 
  Nicolas Serandour, CEO 
 
 
  Allenby Capital Limited (Nominated Adviser 
   & Joint Broker) 
  Nick Athanas / Liz Kirchner / Nicholas Chambers                        Tel: [phone] 
                                                                                        5656 
 
 
  Stifel Nicolaus Europe (Joint Broker) 
  Jonathan Senior                                                   Tel: [phone] 
 
 
  Walbrook PR (Financial PR &                 Tel: [phone] or [e-mail] 
   IR) 
  Paul McManus / Anna Dunphy                             Mob: [phone] / Mob: +44 
                                                                             (0)7876 741 001 
 
 
 

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy in the treatment of cancer, which harnesses the very best in modern technology. Advanced Oncotherapy's R&D team, ADAM, in Geneva, focuses on the development of a proprietary proton accelerator - LIGHT (Linac Image Guided Hadron Technology). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a compact and truly modular unit, offering significant cost advantages. LIGHT also delivers proton beams in a way that facilitates greater precision and electronic control, which are not achievable with currently available alternative technologies.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology, offering better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton or particle therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of cutting edge, cost-effective systems for particle therapy.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

IOELLMATMBIMBAL

(END) Dow Jones Newswires

September 09, 2019 11:48 ET (15:48 GMT)